In the AMPLITUDE-O trial, weekly subcutaneous injections of GLP-1 receptor agonist efpeglenatide (4 or 6 mg) for a median of 1.8 years led to a 27% lower risk of incident MACE and a 32% lower risk of a composite renal outcome event compared to a placebo in patients with T2DM and either a history of cardiovascular disease or current kidney disease [93] (Figure 2). The gene discussed is GLP1R; the disease is kidney disorder.